Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q2 EPS by 5c; Guides FY11
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $240.74 -1.27%
Revenue Growth %: +7.1%
Financial Fact:
Total revenues: 374.18M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +7.1%
Financial Fact:
Total revenues: 374.18M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q2 EPS of $0.82, $0.05 better than the analyst estimate of $0.77. Revenue for the quarter came in at $64.6 million versus the consensus estimate of $61.86 million.
Sees FY2011 EPS of $3.15-$3.25, versus the consensus of $3.07.
Sees FY2011 EPS of $3.15-$3.25, versus the consensus of $3.07.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Nucor projects Q3 2026 earnings above prior year, below estimates
- Jazz Pharmaceuticals (JAZZ) PT Raised to $337 at UBS on GEA Approval for Ziihera
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
